Pharmaceuticals

Deep Vein Thrombosis Global Forecast: Market to Scale Up to $1.37 Billion by 2030 at 4.7% CAGR

February 13, 2026February 13, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the deep vein thrombosis market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Deep Vein Thrombosis Market covering 2026–2035?

The deep vein thrombosis market has demonstrated consistent expansion in recent years. It is projected to increase from $1.09 billion in 2025 to $1.14 billion in 2026, at a compound annual growth rate (CAGR) of 4.0%. This historical growth can be attributed to several factors, including the rising incidence of venous thromboembolism, an aging population leading sedentary lifestyles, an increase in hospital-based surgical procedures, the wider availability of conventional anticoagulants, and growing awareness of DVT complications.

The deep vein thrombosis market is anticipated to experience consistent expansion over the forthcoming years. It is projected to reach a value of $1.37 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.7%. This growth during the forecast period can be attributed to several factors, including advancements in novel anticoagulant therapies, an increasing preference for oral over injectable treatments, the expansion of homecare and remote monitoring solutions, the rise in preventive screening programs, and improved access through online pharmacies. Key trends anticipated in this period involve the growing adoption of direct oral anticoagulants, a shift toward outpatient and home-based DVT management, a heightened focus on early diagnosis and risk stratification, the increasing use of minimally invasive interventional procedures, and the expansion of online and specialty pharmacy channels.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10616&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Deep Vein Thrombosis Market?

The increasing number of individuals who require deep vein thrombosis (DVT) treatment is projected to fuel the growth of the deep vein thrombosis market in the future. DVT treatment involves administering medications, such as anticoagulants and other drugs, to patients with deep vein thrombosis to prevent new blood clots from forming and existing ones from enlarging, thereby alleviating the condition. The rise in patients needing DVT treatment indicates a higher prevalence of deep vein thrombosis, which necessitates products for its diagnosis, prevention, and treatment. For instance, in February 2023, data from the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, showed that an estimated 900,000 people in the United States could be affected annually by deep vein thrombosis, and between 60,000 and 100,000 Americans die each year from DVT or PE (pulmonary embolism). Consequently, the growing number of individuals requiring deep vein thrombosis (DVT) treatment is driving the market.

What Segments Are Identified Within The Structure Of The Deep Vein Thrombosis Market?

The deep vein thrombosis market covered in this report is segmented –

1) By Drug Class: Anticoagulants, Inferior Vena Cava Filters, Other Drug Class

2) By Treatment: Surgery, Drugs, Other Treatments

3) By Mode Of Administration: Injectable, Oral, Other Modes Of Action

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-users

Subsegments:

1) By Anticoagulants: Direct Oral Anticoagulants (DOACs), Vitamin K Antagonists, Low Molecular Weight Heparins, Unfractionated Heparin

2) By Inferior Vena Cava Filters: Retrievable IVC Filters, Permanent IVC Filters, Advanced IVC Filter Systems

3) By Other Drug Class: Thrombolytics, Antiplatelet Agents, Fibrinolytics, Combination Therapy

What Long-Term Trends Are Expected To Shape The Future Of The Deep Vein Thrombosis Market?

Leading companies in the deep vein thrombosis market are prioritizing strategic partnerships to facilitate prompt diagnosis of deep vein thrombosis (DVT) and maximize their market profitability. Such collaborations underscore the increasing focus on leveraging AI and machine learning to advance medical diagnostics, particularly for the rapid and precise identification of DVT. For example, in November 2023, ThinkSono Ltd., a UK-based ultrasound AI company specializing in DVT diagnosis, collaborated with NYU Langone Health, a US-based academic medical center. This partnership launched the initial clinical trial for new artificial intelligence (AI)-powered ultrasound software, designed to enable more rapid and portable diagnosis of deep vein thrombosis (DVT). Through this alliance, the ThinkSono Guidance System technology utilizes AI to potentially detect DVT more quickly, precisely, and affordably than conventional methods. Researchers will employ the ThinkSono Guidance System in conjunction with standard ultrasound scanning in patients both with and without DVT. To evaluate and confirm the ThinkSono system’s accuracy, the performance of these two approaches will be compared. Additionally, medical students from the NYU Grossman School of Medicine will assist in conducting the trial, integrating it into the school’s practical research curriculum.

Which Key Players Are Driving Competition In The Deep Vein Thrombosis Market?

Major companies operating in the deep vein thrombosis market are Abbott Laboratories, Bristol-Myers Squibb Company, Sanofi-Aventis U.S. LLC, Daiichi Sankyo Company Limited, Novartis AG, Mylan N.V., Bayer AG, Boehringer Ingelheim GmbH, Medtronic PLC, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Stryker Corporation, Cook Medical Incorporated, Boston Scientific Corporation, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline plc, Shire Pharmaceuticals, AstraZeneca PLC, Endo International plc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/deep-vein-thrombosis-global-market-report

Which Region Is Projected To Lead The Deep Vein Thrombosis Market During The Forecast Period?

North America was the largest region in the deep vein thrombosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global deep vein thrombosis market report during the forecast period. The regions covered in the deep vein thrombosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Deep Vein Thrombosis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10616&type=smp

Browse Through More Reports Similar to the Global Deep Vein Thrombosis Market 2026, By The Business Research Company

Deep Vein Thrombosis Market Report 2026

https://www.thebusinessresearchcompany.com/report/deep-vein-thrombosis-global-market-report

Venous Thromboembolism Market Report 2026

https://www.thebusinessresearchcompany.com/report/venous-thromboembolism-global-market-report

Thrombophilia Market Report 2026

https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795